Login to Your Account



Potential 'Blockbuster Status'

Algeta-Bayer Prostate Cancer Metastases Trial is Stopped

By Nuala Moran


Wednesday, June 8, 2011
LONDON – Algeta A/S said its lead product Alpharadin is on course for blockbuster status after the Phase III trial was stopped on the basis of statistically significant efficacy in the treatment of bone marrow metastases in patients with castration-resistant prostate cancer. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription